Emerging degrader technologies engaging lysosomal pathways

Targeted protein degradation (TPD) provides unprecedented opportunities for drug discovery. While the proteolysis-targeting chimera (PROTAC) technology has already entered clinical trials and changed the landscape of small-molecule drugs, new degrader technologies harnessing alternative degradation...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Yu, Xing, Dong, Fei, Yiyan, Lu, Boxun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2022
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620493/
https://www.ncbi.nlm.nih.gov/pubmed/36218065
http://dx.doi.org/10.1039/d2cs00624c

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9620493/
https://www.ncbi.nlm.nih.gov/pubmed/36218065
http://dx.doi.org/10.1039/d2cs00624c

Ejemplares similares